GlassScriptPhysician profile
Winnie Sheu Woc
NPI 1295142768
$5,551.46
in general payments reported to CMS, 2019-2025
32 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $1,200 · 2023: $1,485 · 2024: $1,242 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,055 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.64 |
| Education | $149.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.41 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $803.58 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $590.39 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $350.64 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.97 | 2021-2025 | Xifaxan, Trulance, Uceris |
| E.R. Squibb & Sons, L.L.C. | $265.54 | 2024 | Zeposia |
| Lilly USA, LLC | $224.40 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $187.56 | 2022-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $183.80 | 2023-2024 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $182.35 | 2023-2025 | Ocaliva |
| Medtronic, INC. | $127.91 | 2025 | Endoflip |
| Pfizer INC. | $119.59 | 2023-2025 | |
| Ardelyx, INC. | $89.23 | 2022-2024 | Ibsrela |
| Gilead Sciences, INC. | $79.69 | 2023-2025 | |
| Organon LLC | $73.60 | 2022-2025 | Hadlima, Renflexis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $72.96 | 2022 | |
| Celltrion USA INC. | $65.16 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Merck Sharp & Dohme LLC | $63.87 | 2023-2024 | Dificid, Zinplava |
| Celgene Corporation | $58.93 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $48.81 | 2021-2023 | Linzess |
| Fresenius Kabi USA, LLC | $47.95 | 2023 | |
| Aimmune Therapeutics, INC. | $46.55 | 2025 | Zenpep |
| Amgen INC. | $40.47 | 2021-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $35.70 | 2024 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $22.06 | 2025 | Givlaari |
| Pharmacosmos Therapeutics INC. | $19.28 | 2023 | Monoferric |
| Sandoz INC. | $15.75 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.22 | 2023 | Cyltezo |
| Madrigal Pharmaceuticals | $14.73 | 2025 | Rezdiffra |
| Biocon Biologics INC | $14.07 | 2025 | Yesintek |
| Qol Medical, LLC | $13.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.40 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winnie Sheu Woc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.